-+ 0.00%
-+ 0.00%
-+ 0.00%

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Barchart·12/05/2025 08:00:00
Listen to the news

VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS), multiple real world studies on the burden of depression and anti-seizure medication (ASM) titration in epilepsy, and new data for its pre-clinical program in Dravet syndrome. These data are being presented at the American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 in Atlanta, Georgia.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.